US 12,122,918 B2
Drug that reacts with acrolein, use thereof and novel compound
Katsunori Tanaka, Saitama (JP); and Ambara Rachmat Pradipta, Saitama (JP)
Assigned to RIKEN, Saitama (JP)
Appl. No. 17/256,969
Filed by RIKEN, Saitama (JP)
PCT Filed Jul. 5, 2019, PCT No. PCT/JP2019/026838
§ 371(c)(1), (2) Date Mar. 1, 2021,
PCT Pub. No. WO2020/009227, PCT Pub. Date Jan. 9, 2020.
Claims priority of application No. 2018-129372 (JP), filed on Jul. 6, 2018.
Prior Publication US 2021/0179853 A1, Jun. 17, 2021
Int. Cl. C09B 11/24 (2006.01); C07C 15/00 (2006.01); C07C 25/00 (2006.01); C07C 35/00 (2006.01); G01N 1/30 (2006.01); G01N 33/52 (2006.01)
CPC C09B 11/24 (2013.01) [C07C 15/00 (2013.01); C07C 25/00 (2013.01); C07C 35/00 (2013.01); G01N 1/30 (2013.01); G01N 33/52 (2013.01); G01N 2001/302 (2013.01)] 10 Claims
 
1. A drug that reacts with acrolein,
said drug comprising:
a compound having a chemical structure represented by Formula (1):

OG Complex Work Unit Chemistry
wherein
R1 and R2 each independently represent a hydrogen atom, a halogen atom, or an alkyl group that has 1 to 5 carbon atoms and that may be substituted by at least one halogen atom, provided that at least one of R1 and R2 is the alkyl group having 1 to 5 carbon atoms;
R3, R4, and R each independently represent a hydrogen atom, a halogen atom, a hydroxy group, a thiol group, an amino group that may have a substituent, an alkoxy group having 1 to 5 carbon atoms, an alkylthio group having 1 to 5 carbon atoms, or an alkyl group having 1 to 5 carbon atoms provided that a hydrogen atom constituting the alkyl group may be substituted by a substituent selected from a halogen atom, a hydroxy group, and an amino group that may have a substituent;
n is an integer of not less than 1 and not more than 5; and
custom character is a binding site to another chemical structure.